CARDIFF ONCOLOGY, INC. Deferred Tax Liabilities, Other
CARDIFF ONCOLOGY, INC. (CRDF) had Deferred Tax Liabilities, Other of $0 as of 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilitiesOther · last filed 2023-03-02
- 2022-12-31: Deferred Tax Liabilities, Other $0.00.
- 2021-12-31: Deferred Tax Liabilities, Other $0.00.
- 2020-12-31: Deferred Tax Liabilities, Other $6.00K.
- 2019-12-31: Deferred Tax Liabilities, Other $12.00K.
| Period end | Deferred Tax Liabilities, Other |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $6.00K 10-K · filed 2022-02-24 |
| 2019-12-31 | $12.00K 10-K · filed 2021-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |